世界の前臨床CRO (医薬品開発業務受託機関) 市場
Global Preclinical CRO Market Research Report Forecast to 2024
|発行||Market Research Future||商品コード||909752|
|出版日||ページ情報||英文 125 Pages
|世界の前臨床CRO (医薬品開発業務受託機関) 市場 Global Preclinical CRO Market Research Report Forecast to 2024|
|出版日: 2019年07月31日||ページ情報: 英文 125 Pages||
当レポートは世界の前臨床CRO (医薬品開発業務受託機関) 市場について調査しており、市場機会や課題、成長および阻害要因、投資、価格、サービス・治療分野・エンドユーザー・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。
Global Preclinical CRO Market: Information by Service (Toxicology Testing, Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies, Others), Application (Oncology, Central Nervous System (CNS) Disorders, Cardiovascular Diseases, Immunological Disorders, Respiratory Diseases, Infectious Diseases, Diabetes and Others), by End User (Pharmaceutical and Biopharmaceutical Industries, Medical Device Companies and Academic Institutes) and Region - Forecast till 2024
A preclinical CRO distributes the practice, information and ability that is required to take a therapeutic product or a medical device from its clinical stage to advertising or delivery. Benefitting the growth in subcontracting of non-core purposes, improved abilities of preclinical CROs, the global preclinical CRO market has been principally helped to offer supplementary value-added services, rolling number of drugs in the preclinical phase, economies of production & scale, mutual advantage to the contractor as well as the client and high R&D expenditure. However, its has been noted that the shortage of labor as well as high labor cost, operational variations in the industry is predicted to confine the market growth. The global market for preclinical CRO is expected to drive owing to aspects for example development in outsourcing of non-core functions, boosted abilities of preclinical CROs to offer additional value-added services and heaving number of drugs in preclinical stages. Furthermore, economies of production and scale is a shared advantage to the outworker as well as the client and high R&D outflow are expected to fund the growth of the market in the coming years.
The collective urge for experimenting new drugs and chemicals as well as dynamic progress in the pharmaceutical and biopharmaceutical segments are expected to drive the market. However, the bioanalysis and drug metabolism and pharmacokinetics (DMPK) studies section is likely to parade the highest CAGR of 8.96% from 2019 to 2024. Innovative technological advances by various companies to deliver healthier services to pharmaceutical companies and is driving the growth of the sector simultaneously. The Key players in the market segmented, can be given by service (i.e. Toxicology Testing, Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies and others), By Application (Immunological Disorders, Respiratory Diseases, Oncology, Diabetes, Cardiovascular Diseases, Infectious Diseases and others), By End User (Medical Device Companies, Academic Institutes, Pharmaceutical and Biopharmaceutical Industries and others), By Region (North America, Europe, Asia-Pacific and Rest of the World).The SWOT Analysis of the Global Preclinical CRO Market can be further customized and can be available as an additional article into the main report. The toxicological testing segment is projected to head the market and roll a substantial CAGR to reach USD 2,476.28 Million by the end of 2024.
Geographically, the Global Preclinical CRO Market is segmented and targeted into global regions like North America, Asia-Pacific, Middle East and Africa along with the European market. The European market is projected to surpass USD 1,670.19 Million by 2024. The cumulative farm out activities in Europe, low labor cost & engineering cost and accessibility of expert medical force are the reasons driving the growth of the preclinical CRO market in the region. Americas considered to be the largest market share of 40.7% in 2018, and the regional market is projected to list a CAGR of 7.49% throughout the prediction period. Asia-Pacific is expected to register the fastest CAGR. The Indian market is probable to show the uppermost growth rate of 9.44% during the forecast period of 2019 to 2024.
The bulging players in the Global Preclinical CRO Market. Are compnaies like Pharmaceutical Product Development, LLC (US), MD Biosciences (US)., IQVIA (US), PAREXEL International Corporation (US), Envigo (US), Charles River (US), ICON PLC (Dublin), PRA Health Sciences (US), Medpace (US), Laboratory Corporation of America Holdings (US), WuXi AppTec (China) and Eurofins Scientific (Luxembourg. The players operating in the global preclinical CRO market are focusing on product unveilings, along with intensifying their global footpaths by entering untouched markets.